GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Regeneron Pharmaceuticals, Inc. (REGN) [hlAlert]

Rating:
Outperform
REGN
up 617.33 %

Regeneron Pharmaceuticals, Inc. (REGN) upgraded to Outperform with price target $81 by Robert W. Baird

Posted on: Tuesday,  Jan 10, 2012  8:25 AM ET by Robert W. Baird

Robert W. Baird rated Outperform Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on 01/10/2012, when the stock price was $75.00.
Since then, Regeneron Pharmaceuticals, Inc. has gained 617.33% as of 01/27/2016's recent price of $538.00.
If you would have followed this Robert W. Baird's recommendation on REGN, you would have gained 617.33% of your investment in 1478 days.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/10/2012 8:25 AM Buy
None
75.00 81.00
as of 12/31/2012
1 Week down  -1.13 %
1 Month down  -3.10 %
3 Months up  12.05 %
1 YTD up  128.09 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/24/2008 8:25 AM Hold
None
21.72 25.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy